NR1H3 and breast carcinoma: This was systematically observed across all three breast cancer cell lines for all the PSSs tested, but collectively our data indicated that SITO and STAN are more efficient inhibitors of oxysterol driven LXRA activity than the other PSSs assayed (Figure 5, Table S1).